利福平、莫西沙星、乙胺丁醇和阿奇霉素对临床分离的类人猿支原体的协同和叠加作用。

IF 3 3区医学 Q2 INFECTIOUS DISEASES

European Journal of Clinical Microbiology & Infectious Diseases Pub Date : 2025-09-18 DOI:10.1007/s10096-025-05266-7

Hershko Yizhak, Adler Amos

{"title":"利福平、莫西沙星、乙胺丁醇和阿奇霉素对临床分离的类人猿支原体的协同和叠加作用。","authors":"Hershko Yizhak, Adler Amos","doi":"10.1007/s10096-025-05266-7","DOIUrl":null,"url":null,"abstract":"Pulmonary disease caused by Mycobacterium simiae is challenging to treat due to intrinsic resistance and limited guidelines. We assessed synergy among rifampicin, moxifloxacin, ethambutol, and azithromycin using the checkerboard method. Synergy (FICI = 0.5) was found only for the moxifloxacin-ethambutol combination in 63% of 27 clinical isolates, with the remainder showing additive effects. No synergy was observed for rifampicin or azithromycin. These findings suggest potential therapeutic benefit for the moxifloxacin-ethambutol combination, even in non-susceptible isolates, supporting reconsideration of ethambutol in treatment regimens. Clinical studies are needed to validate the observed in vitro synergy.","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synergistic and additive effects of rifampicin, moxifloxacin, ethambutol, and azithromycin against M. simiae clinical isolates.\",\"authors\":\"Hershko Yizhak, Adler Amos\",\"doi\":\"10.1007/s10096-025-05266-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pulmonary disease caused by Mycobacterium simiae is challenging to treat due to intrinsic resistance and limited guidelines. We assessed synergy among rifampicin, moxifloxacin, ethambutol, and azithromycin using the checkerboard method. Synergy (FICI = 0.5) was found only for the moxifloxacin-ethambutol combination in 63% of 27 clinical isolates, with the remainder showing additive effects. No synergy was observed for rifampicin or azithromycin. These findings suggest potential therapeutic benefit for the moxifloxacin-ethambutol combination, even in non-susceptible isolates, supporting reconsideration of ethambutol in treatment regimens. Clinical studies are needed to validate the observed in vitro synergy.\",\"PeriodicalId\":11782,\"journal\":{\"name\":\"European Journal of Clinical Microbiology & Infectious Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Clinical Microbiology & Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10096-025-05266-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Microbiology & Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10096-025-05266-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

由类似性分枝杆菌引起的肺部疾病由于其固有的耐药性和有限的指导方针而具有挑战性。我们使用棋盘法评估利福平、莫西沙星、乙胺丁醇和阿奇霉素之间的协同作用。在27个临床分离株中，只有63%的莫西沙星-乙胺丁醇联用出现协同效应（FICI = 0.5），其余的表现为加性效应。利福平或阿奇霉素未观察到协同作用。这些发现提示莫西沙星-乙胺丁醇联合治疗的潜在疗效，即使在非敏感的分离株中也是如此，支持在治疗方案中重新考虑乙胺丁醇。需要临床研究来验证观察到的体外协同作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Synergistic and additive effects of rifampicin, moxifloxacin, ethambutol, and azithromycin against M. simiae clinical isolates.

Pulmonary disease caused by Mycobacterium simiae is challenging to treat due to intrinsic resistance and limited guidelines. We assessed synergy among rifampicin, moxifloxacin, ethambutol, and azithromycin using the checkerboard method. Synergy (FICI = 0.5) was found only for the moxifloxacin-ethambutol combination in 63% of 27 clinical isolates, with the remainder showing additive effects. No synergy was observed for rifampicin or azithromycin. These findings suggest potential therapeutic benefit for the moxifloxacin-ethambutol combination, even in non-susceptible isolates, supporting reconsideration of ethambutol in treatment regimens. Clinical studies are needed to validate the observed in vitro synergy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Clinical Microbiology & Infectious Diseases 医学-传染病学

CiteScore

10.40

自引率

2.20%

发文量

138

审稿时长

1 months

期刊介绍： EJCMID is an interdisciplinary journal devoted to the publication of communications on infectious diseases of bacterial, viral and parasitic origin.